Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma has completed enrollment of 247 patients in its pivotal Phase 3 trial for Piclidenoson, an oral treatment for moderate-to-severe plaque psoriasis. The study, designed in agreement with the FDA and EMA, will undergo interim analysis evaluating efficacy and safety, with results expected in late 2026 or early 2027. Piclidenoson's or…